Valuation : Entia Biosciences, Inc.

Market Cap 235K 202K 189K 173K 326K 22.49M 327K 2.24M 876K 11.33M 884K 865K 37.51M P/E 2015
-0.97x
P/E 2016 -1.13x
Enterprise Value 1.21M 1.03M 969K 887K 1.67M 115M 1.68M 11.47M 4.48M 58.02M 4.53M 4.43M 192M EV / Sales 2015
8.29x
EV / Sales 2016 9.59x
Free-Float
99.44%
Yield 2015 *
-
Yield 2016 -
1 day+300.00%
Current month+300.00%
1 month+300.00%
3 months+33.33%
6 months+166.67%
Current year+166.67%
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 0.0001
0.04
1 year 0
Extreme 0.0001
0.04
3 years 0
Extreme 1.0E-6
0.04
5 years 0
Extreme 1.0E-6
0.1
10 years 0
Extreme 1.0E-6
0.39
Manager TitleAgeSince
Chief Executive Officer 69 2017-11-27
Change 5-day change 1-year change 3-year change Capi.($)
-50.00%-.--%+700.00%+300.00% 27.25K
+0.10%+0.44%+2.80%+24.32% 50.96B
+2.65%+4.45%+481.36%+567.32% 46.18B
-0.88%+0.90%+24.11%+87.74% 42.73B
+0.33%+2.47%+38.97%+19.80% 43.04B
-2.27%-3.02%+14.22%+51.50% 33.48B
-1.21%-0.17%+29.16%+135.38% 17.28B
-0.36%-2.14% - - 16.43B
+0.25%+0.25%+12.03%+30.68% 14.73B
+0.44%+1.70%+82.07%+47.92% 14.09B
Average +29.91%+0.31%+153.86%+140.52% 27.89B
Weighted average by Cap. +0.04%+0.57%+104.35%+141.83%

Financials

2015 2016
Net sales 347K 298K 279K 255K 481K 33.13M 482K 3.3M 1.29M 16.7M 1.3M 1.27M 55.27M 265K 228K 213K 195K 368K 25.35M 369K 2.53M 988K 12.78M 997K 975K 42.29M
Net income -2.26M -1.94M -1.82M -1.66M -3.13M -216M -3.14M -21.51M -8.41M -109M -8.49M -8.3M -360M -1.4M -1.2M -1.12M -1.03M -1.93M -133M -1.94M -13.28M -5.19M -67.19M -5.24M -5.13M -222M
Net Debt 255K 219K 205K 188K 354K 24.36M 355K 2.43M 949K 12.28M 958K 937K 40.64M 970K 833K 780K 714K 1.34M 92.64M 1.35M 9.23M 3.61M 46.69M 3.64M 3.56M 155M
Logo Entia Biosciences, Inc.
Entia Biosciences, Inc. develops pharmaceutical-grade organic compounds, including a foundational compound called ErgoD2. The Company also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. The Company's ErgoD2 formulations utilize organically cultivated specialty mushrooms available from various domestic and international suppliers. These mushroom-based products are generally regarded as safe (GRAS). The Company's market and scientific research has identified mushroom species and suppliers to provide the nutritional profiles for its ErgoD2 formulations.
Employees
7
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. ERGO Stock